JosephC.LandolfiDOVice President, Chief Medical Officer

PubMed

• 5 citations
  NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials and clin...
  Aly H Abayazeed, Ahmed Abbassy, Michael Müeller, Michael Hill, Mohamed Qayati, Shady Mohamed, Mahmoud Mekhaimar, Catalina Raymond, Prachi Dubey, Kambiz Nael, Saurabh R...> ;Neuro-Oncology Advances. 2022 Dec 20
• 71 citations
  Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Gli...
  Timothy F. Cloughesy, Kevin Petrecca, Tobias Walbert, Nicholas Butowski, Michael Salacz, James Perry, Denise Damek, Daniela A. Bota, Chetan Bettegowda, Jay-Jiguang Zhu...> ;JAMA Oncology. 2020 Dec 1
• 104 citations
  Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
  Andrew Ip, Donald A. Berry, Eric Hansen, Andre Goy, Andrew L. Pecora, Brittany A Sinclaire, Urszula Bednarz, Michael Marafelias, Scott M. Berry, Nicholas S. Berry, Shi...> ;Plos One. 2020 Aug 13
• 135 citations
  A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.
  Patrick Y. Wen, David A. Reardon, Terri S. Armstrong, Surasak Phuphanich, Robert Aiken, Joseph Landolfi, William T. Curry, Jay-Jiguang Zhu, Michael Glantz, David M. Pe...> ;Clinical Cancer Research. 2019 Oct 1
• 116 citations
  Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
  Timothy F. Cloughesy, Joseph Landolfi, Michael A. Vogelbaum, Derek Ostertag, James B. Elder, Stephen Bloomfield, Bob S. Carter, Clark C. Chen, Steven N. Kalkanis, Sant...> ;Neuro-Oncology. 2018 Sep 3
• 126 citations
  Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
  Timothy F. Cloughesy, Joseph Landolfi, Daniel J. Hogan, Stephen Bloomfield, Bob S. Carter, Clark C. Chen, J. Bradley Elder, Steven N. Kalkanis, Santosh Kesari, Albert ...> ;Science Translational Medicine. 2016 Jun 1
• 800 citations
  Maintenance therapy with tumor-Treating fields plus temozolomide vs temozolomide alone for glioblastoma a randomized clinical trial
  Roger Stupp, S. Taillibert, Andrew A. Kanner, Santosh Kesari, David M. Steinberg, Steven A. Toms, Lynne P. Taylor, Frank S. Lieberman, Antonio Silvani, Karen Fink, Gen...> ;JAMA. 2015 Dec 15
• 527 citations
  NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
  Roger Stupp, Eric T. Wong, Andrew A. Kanner, David M. Steinberg, Herbert H. Engelhard, Volkmar Heidecke, Eilon D. Kirson, Sophie Taillibert, Frank Liebermann, Vladimír...> ;European Journal of Cancer. 2012 Sep 1
• 7 citations
  Herpes Encephalitis Masquerading as Tumor
  Tasneem Peeraully, Joseph C. Landolfi> ;ISRN Neurology. 2011 Apr 19
• 28 citations
  Rosai-Dorfman disease manifesting as intracranial and intraorbital lesion.
  Archana Hinduja, L. Giselle Aguilar, Thomas Steineke, David Nochlin, Joseph Landolfi> ;Journal of Neuro-Oncology. 2009 Mar 1
• 41 citations
  Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study.
  Fausto J. Rodriguez, Bernd W. Scheithauer, Robert B. Jenkins, Peter C. Burger, Peter Rudzinskiy, Euvgeni Vlodavsky, Adam Schooley, Joseph Landolfi> ;The American Journal of Surgical Pathology. 2007 Mar 1
• 27 citations
  Paraneoplastic limbic encephalitis and possible narcolepsy in a patient with testicular cancer: Case study
  Joseph Landolfi, Mangala Nadkarni> ;Neuro-Oncology. 2003 Jul 1
• 32 citations
  Chronic malignant pain in cancer patients.
  Joseph C. Landolfi> ;CNS Spectrums. 1999 Sep 1
• Adult brainstem gliomas.
  M C Chamberlain> ;Neurology. 1999 Jul 22
• Adult brainstem gliomas.
  Landolfi JC, Thaler HT, DeAngelis LM> ;Neurology. 1998-10-01
• Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis.
  Mathew, R. M., Vandenberghe, R., Garcia-Merino, A., Yamamoto, T., Landolfi, J. C., Rosenfeld, M. R., Rossi, J. E., Thiessen, B., Dropcho, E. J., Dalmau, J.> ;Neurology. 2007 Mar 20
• Join now to see all

Journal Articles

• Rindopepimut with Temozolomide for Patients with Newly Diagnosed EGFRvIII-expressing Glioblastoma (ACT IV): a Randomized, Double-blind International Phase 3 trial  
  Weller M, Butowski N, Tran DD, et al, Lancet Oncol, 1/22/2017
• Fourth Ventricular Obstruction in Reversible Posterior Leukoencephalopathy Syndrome Following Bevacizumab/FOLFOX  
  Iwuchukwu, I, Landolfi, J, Journal of the NJ Neuroscience Institute, 1/1/2010
• Neuro-Oncology and the Neuro-Oncologist  
  Landolfi JC, Journal of the NJ Neuroscience Institute, 1/1/2008
• Management of Malignant Gliomas: An Update  
  Landolfi JC, Journal of the NJ Neuroscience Institute, 1/1/2008
• Treatment Outcomes of Glioblastoma at a Community Based Teaching Hospital Letter to the Editor  
  Landolfi JC, Journal of the NJ Neuroscience Institute, 1/1/2008
• Diagnostic and Therapeutic Dilemma in a Patient with Intracranial Lesions  
  Marks C, Landolfi JC and Nochlin D, Journal of the NJ Neuroscience Institute, 1/1/2008
• Anti Yo negative paraneoplastic cerebellar degeneration in a patient with gastric cancer  
  Kumar S, Grewal R, Landolfi JC, Journal of Neurological Sciences (Turkish), 1/1/2006
• Trigeminal Neuralgia and Gamma Knife Radiosurgery: The NJNSI Experience  
  Landolfi JC, Zarney S, and Bloomfield S, Journal of the NJ Neuroscience Institute, 1/1/2006
• Join now to see all

Books/Book Chapters

• Meningiomas-Management and Surgery. 
  Chapter: Malignant Meningioma. 
  Levacic D, Nochlin D, Steineke T, Landolfi JIntech Publishing2012

Abstracts/Posters

• Durable Complete Responses Observed in IDH1 Mutated High Grade Glioma at 1st Recurrence undergoing Treatment with Toca 511 & Toca FC.
  Cloughesy TF1, Ostertag D2, Landolfi J3, Walbert T4, Vogelbaum MA5, Elder JB6, Bloomfield S3,Carter B7, Chen CC7, Kalkanis SN4, Kesari S8, Lai A6, Lee IY4, Liau LM1, M..., American Society of Clinical Oncology 53rd Annual Meeting, Chicago, IL, 1/1/2017
• Immunological targeting of CD133 in recurrent glioblastoma: A multi-center Phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy.
  Rudnick J , Fink K, Landolfi J, Markert M, Piccioni D, Glantz M, Swanson S, Gringeri A, Mazanet R, Yu JS, American Society of Clinical Oncology 53rd Annual Meeting, Chicago, IL, 1/1/2017
• Durable responses observed in recurrent high grade glioma (rHGG) with Toca 511 & Toca 5FC treatment.
  Cloughesy TF1, Landolfi J2, Vogelbaum MA3, Ostertag D4, Elder JB5, Bloomfield S2, Carter B6, Chen CC7, Kalkanis SN8, Kesari S9, Lai A1, Lee IY8, Liau LM1, Mikkelsen T8..., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications, Philadelphia, PA, 1/1/2017
• Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/...
  Douglas J. Jolly,1 Manish K. Aghi,2 Michael A. Vogelbaum,3 Steven N. Kalkanis,4 Daniela Bota,5 Bob Carter,6 Clark C. Chen,6 J Bradley Elder,7 Johnathan Engh,8 Samuel G..., American Society of Gene and Cell Therapy, 1/1/2017
• Durable objective responses in IDH wildtype and mutant recurrent high grade glioma with Toca 511 & Toca FC treatment.
  Cloughesy TF, Ostertag D, Landolfi J, Walbert T, Vogelbaum MA, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S,, Lai A, Lee IY, Liau LM, Mikkelsen T, ..., SNO 22nd Annual Meeting, 1/1/2017
• Immunological activation in responding patients with recurrent HGG after treatment with Toca 511 & Toca FC: Results from a phase 1 trial.
  Ostertag, D, Accomando W, Hogan D, Diago O, Gammon D, Haghighi A, Mitchell L, Rodriguez-Aguirre M, Cloughesy TF, Kalkanis SN, Mikkelsen T, Landolfi J, Carter B, Che..., SNO 22nd Annual Meeting, 1/1/2017
• Toca 5: A phase 2/3 randomized, open-label study of Toca 511, a retroviral replicating vector, combined with Toca FC versus standard of care in patients undergoing pla...
  Gelareh Zadeh MD PhD, Daniela Bota MD PhD, David Cachia MD, Joseph Landolfi DO, David Schiff MD, Michael A. Vogelbaum MD PhD, Tobias Walbert MD, David Tran MD PhD, Ali..., American Society of Clinical Oncology 52nd Annual Meeting, Chicago, IL, 1/1/2016
• Complementary clinical and ancillary data from 123 patients with recurrent high grade glioma from three Phase1 trials of Toca 511 and Toca 5FC: Update and justificatio...
  Aghi M, Volelbaum M, Kalkanis S, Bota D, Carter B, Chen C, Elder B, Engh J, Goldlust S, Kaptain G, Kesari S, Landolfi J, Liau L, Mikkelsen T, Piccioni D, Portnow, Sing..., SNO 21st Annual Meeting, 1/1/2016
• Investigation of anti-tumor cellular immune response elicited by Toca 511 & Toca FC therapy in a recurrent HGG phase 1 trial.
  Derek Ostertag1, Timothy F. Cloughesy2, Steven N. Kalkanis3, Tom Mikkelsen3, Joseph Landolfi4, Bob Carter5, Clark C. Chen5, Asha Das1, Harry E. Gruber1, Douglas J. ..., SNO 21st Annual Meeting, 1/1/2016
• Preliminary safety of Toca 511, a retroviral replicating vector, in patients with recurrent high grade glioma across three separate Phase 1 studies.
  Kalkanis S, Aghi MK, Cloughesy T, Kaptain G, Portnow J, Vogelbaum MA, Kesari S, Kalkanis S, Mikkelsen T, Elder JB, Chen CC, Piccioni D, Baskin D, Engh J, Bata D, Chio..., SNO 20th Annual Meeting, Austin, TX, 1/1/2015
• Results of a Dose Escalation Trial of Toca 511 with Toca FC in Recurrent HGG Undergoing Repeat Resection.
  Vogelbaum MA , Kesari S, Kalkanis S, Mikkelsen T, Landolfi J, Elder JB, Chen CC, Robbins JM, Ostertag D, Jolly DJ, Keller MR, Skillings J, Chu A, Cloughesy TF, SNO 20th Annual Meeting, Austin, TX, 1/1/2015
• Combinability of Toca FC and Toca 511 with Chemotherapy and Targeted Agents.
  Kesari S, Landolfi J, Mikkelsen T, Aghi MK, Vogelbaum MA, Elder JB, Cobb C, Singer S, Robbins JM, Ostertag D, Jolly DJ, Chu A, Keller MR, Niethammer A, Cloughesy TF, SNO 20th Annual Meeting; SNO-SCIDOT Joint Conference, Austin, TX, 1/1/2015
• Overall safety and efficacy in subjects with recurrent HGG treated across 2 Tocagen studies – Prognostic Factors associated with survival.
  Landolfi J, Cloughesy T, Vogelbaum MA, Kesari S, Kalkanis S, Portnow J, Mikkelsen T, Elder JB, Baskin D, Chu A, Niethammer A Gruber H, Cobb C, Foltz G, Kaptain G,..., SNO 20th Annual Meeting; SNO-SCIDOT Joint Conference, Austin, TX, 1/1/2015
• The extracellular matrix of glioma tumors influences macrophage activity.
  Previtera M, Sengupta A, Patel R, Mehta P, Peterman K, Hui M, Bloomfield S, Landolfi J, Ewing CA, SNO 20th Annual Meeting; SNO-SCIDOT Joint Conference, Austin, TX, 1/1/2015
• Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.
  Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu JJ, Glantz MJ, 51st Annual ASCO Meeting, Chicago, IL, 1/1/2015
• A randomized, double blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 prolongs progression free survival (PFS) in newly diagnose...
  Hawkins E,…, Landolfi J et al, 50th Annual ASCO Meeting, Chicago, IL, 1/1/2014
• Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high grade glioma.
  Robbins JM, …, Landolfi JC, et al, 50th Annual ASCO Meeting, Chicago, IL, 1/1/2014
• Administration of Toca 511 to subjects with recurrent HGG undergoing repeat resection.
  Cloughesy T, …. Landolfi J et al, SNO 19th Annual Meeting, Miami, FL, 1/1/2014
• A randomized, double blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination ICT-107 following standard treatment in newly diagnosed patients with GBM.
  Wen P, ….Landolfi J et al, SNO 19th Annual Meeting, Miami, FL, 1/1/2014
• Administration of Toca 511 to Subjects with Recurrent HGG Undergoing Repeat Resection- A P1 Study.
  Cloughesy TF,… Landolfi J, et al, American Academy of Neurological Surgeons, 1/1/2014
• A Phase 1 trial of a retroviral replicating vector (Toca 511) demonstrates the importance of real-time MRI-guided delivery for dose related evaluation of safety and ef...
  Aghi MK,…, Landolfi J, et al, American Society of Clinical Oncology 49th Annual Meeting, Chicago, IL, 1/1/2013
• Evidence supporting mechanism of action and drug activity in Phase I trial of patients with recurrent high grade glioma administered Toca 511 at the time of surgical r...
  Cloughesy TF,… Landolfi J, et al, American Society of Clinical Oncology 49th Annual Meeting, Chicago, IL, 1/1/2013
• A Randomized, Double blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT 107 in Newly Diagnosed Patients with Glioblastoma Multiforme Following Resecti...
  Hawkins E,…,Landolfi J et al, American Society of Clinical Oncology 48th Annual Meeting, Chicago, IL, 1/1/2012
• A Case of Kluver-Bucy Syndrome After Unilateral Temporal Lobectomy.
  Dass P , McAbee G, Landolfi J, Research Colloquium, Seton Hall University, 1/1/2012
• A Rare Case of Malignant Central Nervous System Hemangiopericytoma.
  Hassanzadeh B, Tohidi T, Kaleel AS, Mehta S, Landolfi JC, Research Colloquium, Seton Hall University, 1/1/2012
• Join now to see all

Lectures

• Acoustic Neuromas 
  1/1/2017
• Cancer Related Pain 
  1/1/2017
• Current Therapies for Metastatic Brain Tumors 
  1/1/2017
• Current Therapies for Primary Malignant Gliomas 
  1/1/2017
• Diagnosis and Management of Trigeminal Neuralgia 
  1/1/2017
• Epidural Disease and Spinal Cord Compression 
  1/1/2017
• Gamma Knife Radiosurgery for AVM 
  1/1/2017
• Immunotherapy in Gliomas 
  1/1/2017
• Paraneoplastic Syndromes 
  1/1/2017
• Updates on Clinical Trials for Malignant Gliomas 
  1/1/2017
• Use of Gamma Knife Radiosurgery 
  1/1/2017
• Join now to see all

Other

• Brainstem gliomas. 
  Landolfi, J (Edited by Scott H. Plantz MD), E-Medicine on Line
  1/1/2016